142 related articles for article (PubMed ID: 15888749)
1. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer.
Kataja VV; Pavlidis N;
Ann Oncol; 2005; 16 Suppl 1():i43-4. PubMed ID: 15888749
[No Abstract] [Full Text] [Related]
2. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
; Bellmont J; Albiol S
Ann Oncol; 2007 Apr; 18 Suppl 2():ii38-9. PubMed ID: 17491039
[No Abstract] [Full Text] [Related]
3. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
Bellmunt J; Orsola A; Maldonado X; Kataja V;
Ann Oncol; 2010 May; 21 Suppl 5():v134-6. PubMed ID: 20555063
[No Abstract] [Full Text] [Related]
4. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer.
Sengeløv L;
Ann Oncol; 2003 Jul; 14(7):1008-9. PubMed ID: 12853338
[No Abstract] [Full Text] [Related]
5. [The therapeutic dilemma of the early invasive bladder cancer].
Caviezel A; Pelte MF; Fateri F; Iselin C
Rev Med Suisse; 2005 Dec; 1(44):2849-50, 2853. PubMed ID: 16382717
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
Sternberg CN; Parmar MK
J Clin Oncol; 2001 Sep; 19(18 Suppl):21S-26S. PubMed ID: 11560967
[No Abstract] [Full Text] [Related]
7. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
[TBL] [Abstract][Full Text] [Related]
8. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
Heidenreich A
Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722
[No Abstract] [Full Text] [Related]
9. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer.
Herr HW; Scher HI
J Clin Oncol; 1994 May; 12(5):975-80. PubMed ID: 8164050
[TBL] [Abstract][Full Text] [Related]
10. Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?
Galsky MD; Tagawa ST; Shariat SF
J Urol; 2012 Aug; 188(2):358-60. PubMed ID: 22704119
[No Abstract] [Full Text] [Related]
11. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary clinical evaluation of systemic chemotherapy of invasive cancer of the bladder by the CMV protocol].
Szymanowski J; Koźmińska E; Malewski A; Stokłosa A
Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):525-7. PubMed ID: 1282711
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy after cystectomy for bladder tumors staged as superior or equal to pT3].
Schmid HP; Studer UE
Prog Urol; 1997 Feb; 7(1):102-4. PubMed ID: 9116724
[No Abstract] [Full Text] [Related]
14. [Adjuvant and neoadjuvant therapy in bladder and prostatic cancer].
Goepel M; Otto T
Urologe A; 1992 Jul; 31(4):211-2. PubMed ID: 1514203
[No Abstract] [Full Text] [Related]
15. Bladder cancer--resection/ablation.
Corica FA; Keane TE
Surg Oncol Clin N Am; 2005 Apr; 14(2):321-52. PubMed ID: 15817242
[No Abstract] [Full Text] [Related]
16. Management of patients with muscle-invasive and metastatic bladder cancer.
Henry NL; MacVicar G; Hussain M
Oncology (Williston Park); 2005 Sep; 19(10):1333-42; discussion 1342, 1347, 1350 passim. PubMed ID: 16285227
[TBL] [Abstract][Full Text] [Related]
17. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer.
Dreicer R
Semin Urol Oncol; 2001 Aug; 19(3):180-5. PubMed ID: 11561985
[TBL] [Abstract][Full Text] [Related]
19. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.
Amiel GE; Lerner SP
Expert Rev Anticancer Ther; 2006 Feb; 6(2):281-91. PubMed ID: 16445380
[TBL] [Abstract][Full Text] [Related]
20. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
Lagrange JL; Bascoul-Mollevi C; Geoffrois L; Beckendorf V; Ferrero JM; Joly F; Allouache N; Bachaud JM; Chevreau C; Kramar A; Chauvet B;
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):172-8. PubMed ID: 20385453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
